Hereditary Alpha-Tryptasemia · TPSAB1 Copy Number Gain · 1 in 20 Americans
One Gene. Six Systems.
Zero Diagnoses.
HαT drives chronic mast cell activation across every major organ system — the most common cause of elevated basal tryptase, systematically unrecognized in clinical practice
Lower the Tryptase. End the Trypt Chase.
If MTHFR changed how millions of Americans think about genetic variants and chronic illness — HαT may be the variant we haven't caught up to yet. Same prevalence. Stronger mechanistic evidence. Broader systemic impact.
◆ 1 in 20 Americans ◆ Invisible to standard panels ◆ $50 blood test ◆ The Hatters Community ◆ @tryptaseplace
◆
Root Cause
TPSAB1
Extra α-tryptase copies → chronically elevated basal serum tryptase → PAR-2 activation
Overproduction
Excess α-tryptase released constitutively
→
Heterotetramers
α/β hybrid proteins activate PAR-2 with higher potency
→
Cascade
TNF-α, IL-6, IFN-γ · BBB breakdown · Organ inflammation
🧠
Neurological
ADHD, ASD & Neuroinflammation
  • ADHD & ASD features
  • Stimulant non-response
  • Brain fog & sensory dysfunction
  • Anxiety & cognitive impairment
  • Memory impairment (59–68% symptomatic)
✓ Established mechanism
❤️
Autonomic / Cardiovascular
Dysautonomia, POTS & Cardiac Risk
  • Postural orthostatic tachycardia (subset)
  • Lightheadedness & syncope
  • Temperature dysregulation
  • Vasospastic angina — first HαT case 2025
  • Cardiovascular & neuropsychiatric confirmed (Koch et al., Blood 2025)
✓ Documented in cohorts ⚡ Cardiac risk — new 2025
🫙
Gastrointestinal
Gut-Brain Axis Disruption
  • IBS-like symptoms (3–5× general pop.)
  • Chronic abdominal pain & bloating
  • Celiac disease (~5% vs 0.9% general pop.)
  • Persistent symptoms despite GFD
  • Altered GI antibody production
✓ 2026 peer-reviewed
🦴
Connective Tissue
Hypermobility & Immune Overlap
  • Joint hypermobility / hEDS overlap
  • Immune reframe: hEDS as inflammatory disorder (Griggs 2025)
  • Retained primary dentition
  • SLE, Hashimoto's association
  • Specific antibody deficiency
✓ n=266 cohort study ⚡ Immune reframe 2025
🩸
Metabolic — NEW
Type 2 Diabetes & Insulin Resistance
  • Mast cells directly cause T2DM in animals
  • IL-6 & IFN-γ identical to HαT mediators
  • Tryptase elevated in T2DM pancreatic tissue
  • Mast cell stabilizers reversed T2DM
⚡ Hypothesis — unstudied in HαT
🍷
Addiction — NEW
Alcohol Use Disorder & Withdrawal
  • MRGPRX2 drives withdrawal headache
  • HαT upregulates MRGPRX2 in gut
  • Heavy drinking suppresses tryptase (diagnostic hazard)
  • Mast cell stabilizers may ease withdrawal
⚡ Two-step inference — testable
1 in 20
Americans carry HαT
$50
Cost of BST screening test
17
Unstudied research gaps identified
0
FDA-cleared diagnostics
Tryptase Place · Tryptase Place, Parent Advocate & Policy Researcher · April 2026 · tryptaseplace.org · All mechanisms sourced from peer-reviewed literature
HαT
Tryptase Place
Parent Advocate & Policy Researcher
Parent Advocate & Policy Researcher · Texas
Building the scientific and policy case for universal HαT screening. Author of the Generational Load hypothesis paper. Community founder — The Hatters. Contact: tryptaseplace@gmail.com
📸 Instagram 𝕏 X / Twitter ✉ Contact
From Gene to Disease — The HαT Cascade
How One Gene Duplication
Drives Multi-System Illness
Established mechanisms in black. Proposed pathways requiring validation shown in teal.
🧬
Step 1 · Genetic Root
TPSAB1 Copy Number Gain
Extra copies of TPSAB1 produce chronically elevated alpha-tryptase. The more copies, the higher the tryptase — and the more severe the downstream inflammation. Affects ~5% of Western population. Invisible to standard genetic testing.
⚗️
Step 2 · Molecular Activation
α/β Heterotetramer Formation & PAR-2 Activation
Excess alpha-tryptase forces assembly of hybrid α/β tetramers that activate PAR-2 with far greater potency. PAR-2 and EMR2 expressed throughout brain vasculature, gut wall, dural mast cells, vascular endothelium. (Koch et al., Blood 2025)
🔥
Step 3 · Inflammatory Cascade
TNF-α · IL-6 · IFN-γ · MMP-2/9 · Collagen Degradation
PAR-2 triggers sustained TNF-α and IL-6 via NFκB/p38, degrades the blood-brain barrier via MMP-2/MMP-9, and directly cleaves type I and IV collagen via MMP-3 activation (PMID 2553780, PMID 17968569). Continuous proteolytic pressure on connective tissue throughout the body.
🧠
Step 4a · Brain & Nervous System
Blood-Brain Barrier Breakdown & Neuroinflammation
BBB disruption lets systemic cytokines flood the CNS. Mast cell–microglia interactions sustain neuroinflammation in ADHD, ASD, epilepsy (Biomolecules, 2026). Dopamine transporter function impaired. HPA-mast cell feedback loop sustains chronic sympathetic dominance — the stress response that cannot reset.
ADHD ASD Anxiety Alzheimer's risk Treatment-resistant depression
❤️
Step 4b · Cardiovascular — NEW 2025
Vascular Endothelium & Cardiac Risk
PAR-2 and EMR2 on vascular endothelium extends HαT spectrum to cardiovascular, pain, and neuropsychiatric symptoms (Koch et al., Blood 2025). First HαT vasospastic angina case: treatment-resistant coronary disease controlled by antihistamine (Caullery et al., 2025).
Vasospastic angina Vascular inflammation Early cardiac death
🦴
Step 4c · Proposed Pathway — Requires Validation
Craniocervical Ligament Degradation → CCI → Glymphatic Impairment
Tryptase-mediated MMP activation and direct collagen cleavage may produce progressive craniocervical ligamentous laxity (CCI) at C0-C1-C2 — the junction housing primary glymphatic CSF drainage. CCI disrupts this drainage, producing impaired brain waste clearance and chronic neuroinflammation amplification.
Proposed model requiring validation. Individual mechanisms established; HαT-specific pathway unstudied. See Gap 6.
CCI — proposed Glymphatic failure — proposed POTS in subset
🫙
Step 4d · Gut-Brain Axis
MRGPRX2 Upregulation & Gut Mast Cell Sensitization
PAR-2 upregulates MRGPRX2 in enteric mast cells (confirmed 2026, Frontiers in Allergy, n=854). Gut becomes a continuous tryptase source and sensitized site for alcohol-withdrawal mast cell degranulation. Small intestinal immunopathology and altered GI antibody production confirmed (Konnikova et al., JACI 2021).
IBS Celiac modifier Antibody dysregulation GLP-1 disruption
🩸
Step 4e · Metabolic System — NEW
Adipose Mast Cell Activation → Insulin Resistance
IL-6 and IFN-γ from primed mast cells drive insulin resistance and T2DM — demonstrated causally in two strains of mast cell–deficient mice. Tryptase and histamine overexpressed in T2DM pancreatic tissue.
Insulin resistance T2DM risk Beta cell stress
🍷
Step 4f · Addiction Biology — NEW
Dural MRGPRX2 → Withdrawal Amplification → Relapse
Alcohol withdrawal activates dural mast cells via MRGPRX2/MrgprB2, causing severe headaches driving rehabilitation failure (Neuron, 2023). HαT already upregulates MRGPRX2. Heavy drinking also suppresses serum tryptase, masking HαT diagnosis in active drinkers.
Withdrawal severity Relapse risk Diagnostic masking
Scientific Evidence Assessment · April 2026
What We Know vs.
What Must Be Studied
Established in peer-reviewed literature
Biologically plausible — untested in HαT
Direct study does not yet exist
🧠
Neurological
ADHD · ASD · Neuroinflammation
Mast cell–microglia link confirmed in ADHD, ASD & epilepsy (Biomolecules, April 2026)
PAR-2 tryptase inhibition reduces neuroinflammation and hippocampal neurodegeneration
Memory impairment documented in 59–68% of symptomatic HαT patients
Stimulant failure rate in HαT-positive children — mechanistically predicted, unstudied
Lyons et al. Nat Genet 2016; Ocak et al. J Neuroinflammation 2020; Biomolecules 16(4):530, 2026
🫙
Gastrointestinal
IBS · Celiac · IBD · Immune Dysregulation
MRGPRX2 upregulated in HαT intestinal mast cells (Galeas-Pena et al., Front Allergy 2026, n=854)
Small intestinal immunopathology & altered GI antibody production confirmed in HαT (Konnikova et al., JACI 2021)
Celiac disease ~5% in HαT cohorts vs. 0.9% general population
HαT confirmed as GI disease modifier (Simeone et al., Front Allergy 2026)
Simeone et al. Front Allergy 2026; Galeas-Pena et al. Front Allergy 2026; Konnikova et al. JACI 2021
❤️
Autonomic / Cardiovascular
POTS · Vasospastic Angina · Anaphylaxis
HαT independently increases anaphylaxis incidence and severity
HαT extends to cardiovascular, pain and neuropsychiatric symptoms via PAR-2 and EMR2 (Koch et al., Blood 2025)
First HαT vasospastic angina case — treatment-resistant coronary disease controlled by antihistamine (Caullery et al., 2025)
POTS prevalence in HαT — may contribute in a susceptible subset; HαT rates in POTS cohorts comparable to general population in current studies
Koch et al. Blood 2025; Caullery et al. Eur Heart J Case Rep 2025
🔬
Alzheimer's Disease
Neurodegeneration · Cognitive Decline
Masitinib (mast cell inhibitor) slowed Alzheimer's cognitive decline in Phase 3 RCT (Dubois et al., 2023)
Amyloid-β triggers mast cell degranulation; mast cell products drive microglia-mediated neurotoxicity
PAR-2/BBB disruption hallmark of early Alzheimer's — identical to HαT mechanism
HαT prevalence in Alzheimer's cohorts — never measured
Dubois et al. Alzheimers Res Ther 2023; Kothari et al. Cell 2025
🦴
Connective Tissue / Immune
hEDS · Antibody Deficiency · Kawasaki
hEDS is an immune/inflammatory disorder — 80% of differentially expressed proteins linked to immune pathways (Griggs et al., ImmunoHorizons 2025)
Tryptase amplifies vascular wall inflammation — mast cell degranulation augments aneurysm formation; mast cell stabilizers reduce it
Specific antibody deficiency — MCAD and immunoglobulin deficiency cluster together; HαT-specific prevalence unstudied in pediatric SAD
HαT as Kawasaki disease severity modifier — never studied
Griggs et al. ImmunoHorizons 2025; Konnikova et al. JACI 2021
🩸
Type 2 Diabetes — NEW
Insulin Resistance · Beta Cell Stress
Mast cell deficiency prevents T2DM in two mouse strains; MC transfer restores it (Liu et al., Nat Med 2009)
IL-6 and IFN-γ causally required for diet-induced T2DM — same cytokines HαT produces
Tryptase elevated in obese humans (p=0.008); overexpressed in T2DM pancreatic tissue
HαT prevalence in T2DM cohorts — no study exists
Liu et al. Nat Med 2009 (PMC3341969)
The Diagnostic Gap · The HαT Zone · April 2026
The 8.0 ng/mL Blind Spot
Where 1 in 20 people live — often dismissed as "normal" while experiencing systemic biological amplification
The HαT Zone — Where Carriers Live
0 8.0 11.4 20 THE HαT ZONE font-weight="bold" text-anchor="middle">10.8
>10.8
gt;8.0 (HαT Zone)
ng/mL Basal Serum Tryptase
Subject A · April 2026
Standard Normal ◆ HαT Zone Mastocytosis
Standard Lab Interpretation
Normal.
Result: BST in HαT zone. Reference range: <11.4 ng/mL. No further action indicated. Patient discharged without diagnosis.
→ Diagnostic Dead End / Specialist Hopping
Precision Medicine Interpretation
Genetic Carrier. HαT Zone.
A result in the HαT zone in the absence of mastocytosis places this patient squarely in the HαT zone. Current literature supports BST ≥8.0 ng/mL as a clinical flag for HαT consideration (Alheraky 2024: ≥9.2 ng/mL threshold). Reflex to ddPCR TPSAB1 copy number testing indicated.
→ ddPCR Genetic Confirmation → Precision Management
Why the Gap Exists
The 11.4 ng/mL reference range was derived predominantly from white cohorts that did not account for HαT prevalence. The result: 1 in 20 Americans are being told their tryptase is normal while their immune system operates in a state of chronic amplification. The blind spot is not biological. It is methodological. And it is correctable.
The Policy Solution
1. Universal BST screening in high-risk populations — POTS, hEDS, treatment-resistant ADHD, early sobriety, family history of sudden cardiac death.

2. Revised laboratory reporting — flag results ≥8.0 ng/mL for clinical HαT consideration.

3. ddPCR reflex testing — covered diagnostic procedure for confirmed HαT zone results.
◆
My result placed me in the HαT zone. In a standard lab, I'm 'normal.' In precision medicine, I'm the 1 in 20. We need ddPCR genetic testing to stop the 4-generation cycle. We can't treat what we don't test.
The Generational Load — Subject A Family Case Study · April 2026
Same Gene. Same Cascade.
Four Different Clinical Pictures.
HαT produces a constitutively amplified mast cell system that expresses differently across each generation's trigger landscape. This case study is illustrative of observed patterns in one HαT-affected family.
Generation 1 — The Root
Maternal Ancestor
Early-onset periodontitis. Hypermobility. Connective tissue fragility at its most peripheral — systemic enough to suggest a modifier at work, not dramatic enough to generate a diagnosis. The gene is present. The cascade is quiet. The clock has started.
Undetected Carrier
Generation 3 — The Subject
Subject A · Age 35 · BST in HαT Zone
POTS. Hypermobility. Autonomic instability. Postpartum trigger. "Normal" by standard lab interpretation. In precision medicine — the 1 in 20. One year older than her father when he died. The cascade is named. The cycle ends here.
BST in HαT Zone
Generation 2 — The Peak
Father — Sudden Cardiac Death at 34
Tryptase-mediated vascular inflammation. Connective tissue fragility at the aortic root. Autonomic instability. None of it measured. None of it named. The cascade reached the cardiovascular system and nobody was looking. He was 34. The critical turning point.
Fatal Expression — Unmeasured
Generation 4 — The Future
Child of Subject A
Born into a uterine environment primed with elevated tryptase. Immune system calibrated toward overreaction from birth. Pediatric ADHD. Dysautonomia. Stimulant failure. Still young enough that early identification changes everything.
Early Identification = Intervention
Collateral Branch — Subject A's Brother & His Children
Subject A's Brother
Confirmed Multi-System Presentation
Marfan Syndrome · hEDS · Cutis Laxa · CVID. Full constellation of connective tissue and immune findings consistent with HαT as upstream modifier. Untested.
Niece 1
Specific Antibody Deficiency
HαT directly alters GI antibody production and immune regulation (Konnikova et al., JACI 2021). MCAD and immunoglobulin deficiency cluster at high rates. HαT as upstream modifier — BST not yet measured. → Gap 16
Niece 2
Kawasaki Disease in Infancy
Tryptase amplifies vascular wall inflammation and endothelial injury central to Kawasaki pathology. Mast cell degranulation augments coronary aneurysm formation; mast cell stabilizers reduce it. → Gap 17
Proposed Tryptase-Mediated Cascade — Hypothesis Paper (April 2026)
TPSAB1
Copy Gain
→
Elevated
Tryptase
→
PAR-2 +
MMP Activation
→
Craniocervical
Ligament Laxity*
→
Glymphatic
Impairment*
→
Neuro-
inflammation
→
Autonomic
Dysregulation
→
Multi-System
Downstream
Established in peer-reviewed literature
* Proposed pathway requiring validation
◆
Subject A is 35. Her father died at 34. We are not treating ten diseases. We are missing one modifier. The cycle ends here.
The Addiction–HαT Connection · Published in Neuron 2023
The Receptor That Links
HαT to Alcohol Relapse
MRGPRX2 — already upregulated in HαT — is the same receptor that drives withdrawal headache and rehabilitation failure
🧬
What HαT Does to MRGPRX2
HαT significantly upregulates MRGPRX2 expression in intestinal mast cells — confirmed by spatial transcriptomics and CyTOF mass cytometry (Galeas-Pena et al., Frontiers in Allergy 2026, n=854). The receptor is sensitised and primed before any alcohol exposure.
🍺
The Diagnostic Trap
Heavy alcohol consumption reduces serum basal tryptase. A patient with 4 TPSAB1 copies drinking heavily daily may test below the 8 ng/mL threshold — told they don't have HαT. The ddPCR assay is unaffected by this confound.
🏥
Sobriety Unmasks HαT
Alcohol may have been acting as inadvertent mast cell stabilization for years. When HαT carriers get sober, new-onset POTS, eczema, GI dysfunction, and autonomic instability may represent unmasked HαT — not PAWS alone. Biology, not failure of will.
🔴
MRGPRX2
Mast cell receptor
The pivot point
🍷
What Alcohol Withdrawal Does
Alcohol withdrawal activates MRGPRX2/MrgprB2 on dural mast cells, triggering degranulation and trigeminal neuron sensitisation — causing severe headache. Mice lacking this receptor had zero withdrawal headache behaviours. (Son et al., Neuron 2023)
🔄
The Relapse Cycle
Withdrawal pain → drink to relieve pain → pain relief reinforces drinking → dependence deepens. In HαT, MRGPRX2 is already upregulated. More severe withdrawal pain = stronger drive to resume drinking. Biology, not willpower.
💊
The Testable Treatment
Mast cell stabilisers (cromolyn, ketotifen) — already used off-label in HαT — directly target the mechanism. Testing whether they reduce withdrawal severity is actionable today.
⚠️
Critical clinical note: If a patient presents for alcohol use disorder assessment, standard BST screening may be falsified by their drinking. Always use ddPCR TPSAB1 copy number analysis in active drinkers — it is not affected by alcohol-induced tryptase suppression. HαT may be driving both the disorder and the diagnostic invisibility simultaneously.
The Scientific Emergency — April 2026
What We Know vs.
What We're Missing
The mechanism is established. The population is identifiable. The tools exist. The studies have not been done.
✓ What Is Already Established
1
Mast cells directly cause T2DM
Two strains of MC-deficient mice failed to develop diet-induced diabetes. MC transfer restored it. Cromolyn and ketotifen reversed pre-established T2DM.
Liu et al., Nat Med 2009
2
MRGPRX2 mediates withdrawal headache
MrgprB2-deficient mice showed zero withdrawal headache behaviours. Dural mast cell degranulation entirely receptor-dependent.
Son et al., Neuron 2023
3
HαT upregulates gut MRGPRX2
Spatial transcriptomics and CyTOF confirmed significantly increased MRGPRX2 in HαT intestinal mast cells (n=854 IBD biobank).
Galeas-Pena et al., Front Allergy 2026
4
Heavy drinking suppresses serum tryptase
Active heavy drinkers may have BST below the 8 ng/mL HαT threshold — causing false negatives. ddPCR is unaffected.
Beceiro et al., Alcohol Clin Exp Res 2015
5
Masitinib slowed Alzheimer's in Phase 3 RCT
First successful Phase 3 AD trial targeting innate immune cells. Benefit specifically mast-cell mediated (–2.15 ADAS-cog, p<0.001).
Dubois et al., Alzheimers Res Ther 2023
6
HαT confirmed as cardiac risk modifier
First published HαT vasospastic angina case. HαT confirmed to extend to cardiovascular and neuropsychiatric symptom domains via PAR-2/EMR2.
Caullery et al., Eur Heart J Case Rep 2025; Koch et al., Blood 2025
7
hEDS is an immune/inflammatory disorder
80% of differentially expressed proteins in hEDS linked to immune/inflammatory pathways, complement dysregulation, and mast cell crosstalk.
Griggs et al., ImmunoHorizons 2025
8
Tryptase degrades connective tissue via MMP cascade
Tryptase activates MMP-3 → collagenase; directly degrades type I and IV collagen; activates proMMP-9. Continuous proteolytic pressure on periarticular matrix.
PMID 2553780; PMID 17968569
9
HαT alters GI antibody production
HαT carriers show increased class-switched memory B cells, intestinal immunopathology, and GI-associated autoantibody profiles — suggesting gut barrier impairment and immune dysregulation.
Konnikova et al., JACI 2021
✕ What Has Never Been Studied
1
HαT prevalence in treatment-resistant ADHD/ASD
No large-scale ddPCR prevalence study in treatment-resistant neurodevelopmental cohorts. Central policy ask — most fundable.
Proposed: NIH/ARPA-H grant, n=2,000+
2
HαT prevalence in preeclampsia
Labor is one of the most significant mast cell triggers in the human lifespan. Whether HαT predicts preeclampsia severity is unstudied.
Proposed: ddPCR in obstetric cohorts
3
HαT prevalence in AUD treatment cohorts
No study has tested TPSAB1 copy number in alcohol use disorder populations or correlated it with withdrawal severity or relapse rates.
Proposed: ddPCR in AUD treatment registries
4
Mast cell stabilisers for alcohol withdrawal
No trial has tested cromolyn or ketotifen for reducing withdrawal severity or relapse. The Son et al. mechanism makes this directly actionable.
Proposed: RCT in AUD patients
5
HαT and craniocervical instability — tryptase mechanism
Whether chronic tryptase-mediated collagen degradation produces progressive craniocervical ligamentous laxity in HαT carriers — the proposed key mechanistic link to dysautonomia and glymphatic impairment. Untested.
Proposed: Upright MRI in HαT-confirmed carriers
6
HαT as cardiac risk modifier — population level
Whether HαT-positive individuals have elevated rates of vasospastic cardiac events — potentially explaining premature cardiac death in young adults — never studied in a cohort.
Proposed: Retrospective ddPCR in sudden cardiac death registries
7
HαT in Alzheimer's cohorts
No study has measured TPSAB1 copy number in AD patients. Memory impairment in 59–68% of symptomatic HαT has never been followed longitudinally.
Proposed: Retrospective ddPCR in masitinib trial samples
8
HαT prevalence in pediatric specific antibody deficiency
MCAD and immunoglobulin deficiency cluster at high rates. HαT directly alters antibody production. Whether HαT drives SAD in pediatric primary immunodeficiency populations — never studied.
Proposed: ddPCR in pediatric immunology cohorts — Gap 16
9
HαT as severity modifier in pediatric Kawasaki disease
Tryptase amplifies vascular wall inflammation central to Kawasaki pathology. Whether HαT predicts severity and aneurysm risk in Kawasaki disease — never studied.
Proposed: ddPCR in Kawasaki disease registries — Gap 17
The Tools Exist. The Studies Do Not.
ddPCR TPSAB1 genotyping was validated in 2024. The NIH HαT cohort already exists. Every unstudied gap above is actionable within 12–18 months with existing infrastructure. Full hypothesis paper available at tryptaseplace.org .
9
Established findings
17
Research gaps identified
$50
BST screening test
$0
New drugs needed